Dyne Therapeutics, INC. 8-K Filing
Ticker: DYN · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2024 |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Dyne Therapeutics, INC. (ticker: DYN) to the SEC on Sep 3, 2024.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ange on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob).
How long is this filing?
Dyne Therapeutics, INC.'s 8-K filing is 6 pages with approximately 1,874 words. Estimated reading time is 7 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,874 words · 7 min read · ~6 pages · Grade level 13.8 · Accepted 2024-09-03 07:16:35
Key Financial Figures
- $0.0001 — ange on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob
Filing Documents
- d786894d8k.htm (8-K) — 43KB
- d786894dex991.htm (EX-99.1) — 27KB
- d786894dex992.htm (EX-99.2) — 30KB
- g786894dsp1.jpg (GRAPHIC) — 10KB
- g786894ex99_2p10g1.jpg (GRAPHIC) — 341KB
- g786894ex99_2p11g1.jpg (GRAPHIC) — 392KB
- g786894ex99_2p12g1.jpg (GRAPHIC) — 178KB
- g786894ex99_2p13g1.jpg (GRAPHIC) — 173KB
- g786894ex99_2p14g1.jpg (GRAPHIC) — 217KB
- g786894ex99_2p15g1.jpg (GRAPHIC) — 261KB
- g786894ex99_2p16g1.jpg (GRAPHIC) — 278KB
- g786894ex99_2p17g1.jpg (GRAPHIC) — 286KB
- g786894ex99_2p18g1.jpg (GRAPHIC) — 337KB
- g786894ex99_2p19g1.jpg (GRAPHIC) — 291KB
- g786894ex99_2p1g1.jpg (GRAPHIC) — 392KB
- g786894ex99_2p20g1.jpg (GRAPHIC) — 209KB
- g786894ex99_2p21g1.jpg (GRAPHIC) — 219KB
- g786894ex99_2p22g1.jpg (GRAPHIC) — 188KB
- g786894ex99_2p23g1.jpg (GRAPHIC) — 324KB
- g786894ex99_2p24g1.jpg (GRAPHIC) — 263KB
- g786894ex99_2p25g1.jpg (GRAPHIC) — 311KB
- g786894ex99_2p26g1.jpg (GRAPHIC) — 389KB
- g786894ex99_2p2g1.jpg (GRAPHIC) — 744KB
- g786894ex99_2p3g1.jpg (GRAPHIC) — 188KB
- g786894ex99_2p4g1.jpg (GRAPHIC) — 315KB
- g786894ex99_2p5g1.jpg (GRAPHIC) — 283KB
- g786894ex99_2p6g1.jpg (GRAPHIC) — 188KB
- g786894ex99_2p7g1.jpg (GRAPHIC) — 388KB
- g786894ex99_2p8g1.jpg (GRAPHIC) — 307KB
- g786894ex99_2p9g1.jpg (GRAPHIC) — 369KB
- 0001193125-24-211534.txt ( ) — 11047KB
- dyn-20240831.xsd (EX-101.SCH) — 3KB
- dyn-20240831_lab.xml (EX-101.LAB) — 18KB
- dyn-20240831_pre.xml (EX-101.PRE) — 11KB
- d786894d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit Number Description 99.1 Press Release, dated September 3, 2024. 99.2 Presentation, dated September 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: September 3, 2024 By: /s/ John Cox Name: John Cox Title: President and Chief Executive Officer